You just read:

ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial

News provided by

ImmunoCellular Therapeutics, Ltd.

Jun 21, 2017, 06:00 ET